Atlantic Cancer Consortium

Officially designated as a member of the Marathon of Hope Cancer Centres Network (MOHCCN) in December 2022, the Atlantic Cancer Consortium (ACC) shares the MOHCCN vision to unite Canada to cure cancer. We are aligned with the MOHCCN mission to create a national network that applies world-leading science to cancer care, with a focus on precision medicine. We have rallied our region’s leading cancer researchers, institutions and care facilities to unite around this vision to enhance inter-institutional and inter-provincial cancer research collaboration, to increase cancer research capacity and productivity and to train the next generation of ACC cancer researchers in precision medicine.

As the smallest region joining the MOHCCN, Atlantic Canada has always taken a regionally collaborative approach to cancer research. Assembling our collective critical mass has been essential to creating a thriving cancer research environment. With the MOHCCN, the ACC is excited to contribute to the advancement of cancer research nationally through the engagement with rural and underserved communities to deliver precision oncology opportunities, engagement with Indigenous communities to develop a framework for collaboration, and the implementation of precision medicine in the clinical setting, immunology, metabolism, and biomarkers.


  • Atlantic Cancer Research Institute
  • Dalhousie University
  • Eastern Health
  • Horizon Health
  • Memorial University of Newfoundland
  • Nova Scotia Health
  • University of Prince Edward Island
  • Vitalité Health Network


ProjectsProject leads
TFRI Atlantic Canada Myeloma CohortManal Elnenaei, Tony Reiman
Deciphering (epi)genetics interplay in colorectal cancerTouati Benoukraf, Sevtap Savas
Investigating Serial plasma extracellular vesicle Genomics in High-Grade astrocytoma Tumors (IN-SIGHT)Jeremy Roy, Adrienne Weeks
Liquid biopsy for the detection of drug-targetable mutation in lung cancer patientsZhaolin Xu, Michael Carter
Genetic and environmental factors driving hematologic cancer rates in Atlantic CanadaAmy Trottier, Graham Dellaire
Genetic and Environmental factors driving Lung Cancer Rates in Atlantic CanadaGraham Dellaire, Alison Wallace, Victor Martinez
High parameter spatial biology for assessment of immune contextureDirk Arnold, Jeanette Boudreau, Sidney Croul, Dan Gaston
Defining the Prevalence and Function of the Serine Biosynthesis Pathway Across Breast Cancer Molecular SubtypesPatrick Murphy and Marya Ahmed
Identification of Novel Targets in Primary and Metastatic Breast CancersMarya Ahmed
Profiling the coding and long non-coding transcriptome to identify novel genetic mediators of breast tumor immune suppressionPaola Marcato, Gregory Knapp, Gillian Bethune, Tobias Karakach
Pan-cancer extracellular vesicle (EV) liquid biopsy signatures as predictors of response to immune checkpoint inhibitorsRodney J Ouellette, Jeanette Boudreau, Catherine Taylor, Michael Ha, Alexi Surette, Nicholas Finn, Mahmoud Abdelsalam
The use of extracellular vesicles to improve breast cancer screening and monitoringSherri Christian
Oncometabolomics Profiling ProgramPinto, El Hiani, Marcato, Murphy, Karakach, Brunt, Kienesberger, Brown, Xu, Reiman, Gujar and Pulinilkunnil